Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00202917
Status:
COMPLETED
Last Update Posted:
2014-05-29
First Post:
2005-09-12
Brief Title:
Haploidentical Transplantation With CD3CD19 Depleted Grafts in Patients With Hematologic Malignancies
Sponsor:
University Hospital Tuebingen
Organization:
University Hospital Tuebingen
Study Overview
Official Title:
Multicenter Phase III Study of Haploidentical Hematopoietic Cell Transplantation With CD3CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to study the feasibility and Toxicity of allogeneic haploidentical hematopoietic cell transplantation with CD3CD19 depleted stem cells and a dose reduced conditioning
Detailed Description:
Transplantation of a CD3CD19 depleted stem cell grafts after dose reduced conditioning for the treatment of treatment refractory or relapsed hematologic malignancies after preceding allogeneic or autologous hematopoietic cell transplantation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HSZ-001 | None | None | None |
| IRB Project Nr 212004 | None | None | None |